Biogen and UCB's dapirolizumab pegol flunks mid-stage lupus study Seeking Alpha, 23 Oct 2018 Biogen (NASDAQ:BIIB) and development partner UCB (OTCPK:UCBJF) announce that a Phase 2b clinical trial evaluating dapirolizumab…